Citations

Mayo Clinic

Clear

1818 citation(s) found for "Israel, E".

Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Lee, Ikjae , Jang, Grace E. , Sherman, Alexander , Johnston, Wendy , Fernandes, Joseph Americo, Habib, Ali A. , Maragakis, Nicholas J. , Shah, Jaimin , Zinman, Lorne , Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Heiman‐Patterson, Terry , Jawdat, Omar, Kasarskis, Edward J. , Kisanuki, Yaz Y. , Wymer, James , Fournier, Christina , Hayat, Ghazala , Heitzman, Daragh, Lomen‐Hoerth, Catherine , Pulley, Michael , Scelsa, Stephen N. , Walk, David , Shoesmith, Christen , Sorenson, Eric J. , Elman, Lauren , Harms, Matthew , Hoover, Benjamin N., Yun, RN ByoungSook, Santella, Regina M. , Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Diaz, Frank , Maragakis, Nicholas , Oskarsson, Björn , Goutman, Stephen A , Sorenson, Eric, Walk, David , Cheung, Ken , Diaz, Frank , Fernandes, J. Americo, Paganoni, Sabrina , Burke, Katherine M. , Oskarsson, Björn , Goutman, Stephen A. , Simmons, Zachary , Harms, Matthew B. , Hoover, Benjamin N., Group, for the PLS NHS Study

Annals of Neurology | September 29, 2025 | Volume: 99 | Issue: 2 | Pages: 418-428

10.1002/ana.78056 | PMID 41020440 Get It

Objective The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3‐, 6‐, 9‐, and 12‐month follow‐up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed‐effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS . Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors
Ssebyala, Shakirah N. , Zheng, Yue , Riley, Elizabeth , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Borges, Virginia F. , Partridge, Ann H. , Rosenberg, Shoshana M. , Peppercorn, Jeffrey M , Schapira, Lidia , Come, Steven , Borges, Virginia F , Partridge, Ann H , Rosenberg, Shoshana , Zheng, Yue , Tamimi, Rulla M.

JCO Oncology Practice | September 24, 2025 | Volume: 22 | Issue: 7 | Pages: 1286-1294

10.1200/op-25-00288 | PMID 40991876 Get It

PURPOSE Given the extended survivorship of young adults with breast cancer, characterizing health care utilization and adherence to surveillance guidelines can inform gaps in care. PATIENTS AND METHODS Patients age 40 years and younger at diagnosis of stage 0-III breast cancer enrolled in a prospective cohort study completed a survey 7 years after diagnosis assessing receipt of care and surveillance. We evaluated factors associated with transition to a primary care provider (PCP) for cancer-related follow-up and adherence to mammography and bone density scans. RESULTS Among 660 women, 92% reported having a PCP, although for cancer-related follow-up, 57% saw only an oncology provider, 29% saw both a PCP and oncology provider. In the past 2 years, 68% reported getting a flu shot, 76% a pap test/pelvic examination, 56% cholesterol screening, and 42% (n = 232 endocrine therapy [ET] users) a bone density scan. Among women who had a unilateral mastectomy or lumpectomy (n = 356), 82% reported a mammogram in the past year. In multivariate analyses, those with stage 0 ( v I disease) were more likely to see a PCP for follow-up ( v PCP + oncology provider); ET users and those more concerned about recurrence were less likely. Patients with human epidermal growth factor receptor 2-positive (HER2) disease were more likely to adhere to mammography; those with a BRCA mutation and those with a unilateral mastectomy were less likely. Patients with a BRCA mutation and who had chemotherapy were more likely to report a bone density scan. CONCLUSION Although most have a PCP, over half of young survivors continue to see an oncology provider for follow-up in long-term survivorship. Mammography uptake was high; uptake of other health maintenance practices was lower. Identification of barriers/facilitators to receipt of guideline-concordant care may inform strategies to optimize survivorship.
Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, The EPI Study, Baz, Maher, Byers, Derek E. , Hachem, Ramsey R. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, The EPI Study

Transplantation Direct | September 19, 2025 | Volume: 11 | Issue: 10 | Pages: e1857

10.1097/txd.0000000000001857 | PMID 40989076 Get It

BACKGROUND. We developed a prospective, multicenter “registry” to evaluate the effect of extracorporeal photopheresis for lung transplant recipients who develop chronic lung allograft dysfunction (CLAD) with the bronchiolitis obliterans syndrome (BOS) phenotype (CLAD/BOS) and who are refractory to conventional standard-of-care therapy. METHODS. Data from 258 lung transplant recipients enrolled in the Registry between April 2015 and April 2022 were included in this analysis. All recorded parameters (eg, demographics), including forced expiratory volume in 1 s (FEV1) measurements and indices (FEV1% baseline, FEV1 rate of decline) at several time periods, were included in multivariate linear/logistic and Kaplan-Meier analyses to evaluate potential associations with survival. RESULTS. Mortality at 6 and 12 mo after CLAD/BOS diagnosis was 5% and 14%, whereas mortality at 6 and 12 mo after enrollment was 15% and 26%, respectively. The primary cause of death in the cohort was respiratory failure or graft failure (74%). Rate of FEV1 decline (log) at enrollment was independently associated with survival (log days) from CLAD/BOS diagnosis and enrollment (r = 0.55 and r = 0.3, respectively). The rates of FEV1 decline among survivors were lower (–77 ± 89 mL/mo) compared with nonsurvivors (–148 ± 155 mL/mo) at 6 mo after enrollment (P = 0.0001). CONCLUSIONS. The rate of FEV1 decline quantified using at least 5 FEV1 measurements is a robust surrogate outcome. We plan to use these findings to revise our randomized controlled trial to facilitate risk adjustment using FEV1 rate of decline strata at enrollment and as a scientifically valid surrogate for outcome.
Procedure duration predicts outcomes more than prehospital delay in endovascular stroke treatment
Saad, Hassan , Koo, Andrew B. , Grossberg, Jonathan A , Tianwen, Ma, Howard, Brian M. , Sowlat, Mohammad‐Mahdi , Baba, Bachar El , Chacón, Ariana , Jabbour, Pascal , Rai, Ansaar , Dye, Justin , Alaraj, Ali , Cawley, C. Michael , Tong, Frank , Akbik, Feras , Pabaney, Aqueel, Ezzeldin, Mohamad , Kim, Joon‐Tae , Siddiqui, Fazeel , Maier, Ilko , Park, Min S. , Psychogios, Marios‐Nikos, Wolfe, Stacey Q , Starke, Robert M. , Tanweer, Omar , Polifka, Adam , Mokin, Maxim, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Ma, Tianwen , El Baba, Bachar , Fiorella, David , Yoshimura, Shinichi , Kim, Joon-Tae , Arthur, Adam Stephen , Fragata, Isabel , Siddiqui, Fazeel M , Matouk, Charles , Maier, Ilko , Levitt, Michael R , Grandhi, Ramesh , Wolfe, Stacey Quintero , Shaban, Amir , Navia, Pedro , Osbun, Joshua W , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Alawieh, Ali M , Alaraj, Ali , Sowlat, Mohammad-Mahdi , Howard, Brian M , Koo, Andrew B , Chacón-Aponte, Ariana Alejandra , Jabbour, Pascal , Fiorella, David , Yoshimura, Shinichi , Goyal, Nitin , Fragata, Isabel , Mascitelli, Justin R , Matouk, Charles , Levitt, Michael R. , Grandhi, Ramesh , Samaniego, Edgar A , Romano, Daniele G, Navía, Pedro , Cuellar, Hugo , Moss, Mark E, Limaye, Kaustubh , Mokin, Maxim , Gory, Benjamin , Alawieh, Ali

Journal of NeuroInterventional Surgery | September 19, 2025 | Volume: 18 | Issue: 6 | Pages: 1494-1502

10.1136/jnis-2025-023906 | PMID 40973492 Get It

Background Endovascular thrombectomy (EVT) has transformed acute ischemic stroke (AIS) care, with onset-to-puncture (OTP) time widely recognized as a critical determinant of outcome. However, emerging evidence suggests that in-hospital procedure time (PT)—from arterial puncture to final recanalization—may have an equally or more significant impact. This study examines the relative contribution of PT versus OTP to functional outcomes in patients with AIS undergoing EVT. Methods A retrospective analysis was conducted of 6644 patients with AIS treated at 44 international stroke centers from the Stroke Thrombectomy and Aneurysm Registry (STAR; 2016–2023). Multivariable regression, time-equivalence analysis, and marginal effects modeling were used to assess associations between PT, OTP, and 90-day modified Rankin Scale (mRS) outcomes. Centers were stratified by procedural efficiency and compared using propensity score matching (PSM). Mediation analysis evaluated whether PT accounted for inter-center differences. Results PT and OTP were independently associated with functional outcomes; however, PT had a significantly stronger effect (adjusted OR for mRS 0–2: PT=0.56 vs OTP=0.96 per hour). Each 5 min increase in PT was equivalent to 78–100 min of additional OTP in outcome impact. Centers with faster average PT had higher rates of functional independence (number needed to treat (NNT)=10), fewer complications, and lower symptomatic intracranial hemorrhage rates. PT significantly mediated the relationship between center tier and outcomes (Sobel’s P<0.001). Conclusion While minimizing OTP remains important, PT exerts a greater influence on outcomes after EVT. Procedural efficiency should be emphasized in stroke systems of care and included in center performance metrics to improve patient outcomes.
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Blechter, Batel , Wang, Xiaoyu , Karsonaki, Christiana, Shi, Jianxin , Shiraishi, Kouya , Choi, Jiyeon , Matsuo, Keitaro , Chen, Tzu‐Yu , Kim, Young Tae , Choudhury, Parichoy Pal , Williams, Jacob , Landi, Maria Teresa , Yin, Zhihua , Zhou, Baosen , Seow, Wei Jie , Song, Lei , Chang, I‐Shou , Chien, Li-Hsin , Wong, Maria Pik , Richardson, Brian Douglas , Li, Shilan , Breeze, Charles E. , Bassig, Bryan A. , Sm, Jason Yy Wong, Chung, Lap Ping, Zhang, Xu‐Chao , Caporaso, Neil E. , Chang, Jiang , Ho, Jcm , Momozawa, Yukihide , Kobayashi, Masashi , Okubo, Kenichi , Honda, Takayuki , Kunitoh, Hideo , Watanabe, Shun-ichi, Hamamoto, Ryuji , Goto, Kōichi , Minamiya, Yoshihiro, Wakai, Kenji , Murakami, Yoshinori , Shimizu, Kimihiro , Suzuki, Hiroyuki , Ohtaki, Yoichi , Tanaka, Kazumi , Wu, Tangchun , Wei, Fusheng, Kim, Yeul Hong , Chang, Gee-Chen , Chen, Kuan‐Yu, Chen, Yuh-Min, Park, Jae Yong , Kweon, Sun-Seog, Gao, Yu‐Tang , Schwartz, Ann G. , Gorlov, Ivan , Wu, Xifeng , Yang, Ping , Lam, Stephen , Bojesen, Stig E. , Ji, Bu‐Tian , Wichmann, H. E., Christiani, D.C., Brennan, Paul , McKay, James , Field, John K. , Shete, Sanjay , Marchand, Loı̈c Le, Liu, Geoffrey , Andrew, Angeline S. , Zienolddiny-Narui, Shan, Grankvist, Kjell , Taylor, Fiona, Aldrich, Melinda C. , Jeon, Hyo‐Sung, Hu, Zhibin , Burdett, Laura, Yeager, Meredith, Hutchinson, Amy , Hicks, Belynda , Liu, Jia , Berndt, Sonja I, Wu, Wei , Wang, Junwen , Choi, Jin Eun , Park, Kyong Hwa , Sung, Sook Whan , Tan, Wen , Sihoe, Alan , Choi, Yi Young, Hung, Hsiao-Han , Vermeulen, Roel , Wu, Junjie , Tsai, Fang-Yu , Chan, John K. C., Li, Jihua , Lin, Hsien-Chih, Liu, Jie , Sawada, Norie , Yamaji, Taiki , Wyatt, Kathleen , Qi, T. Y., Li, Xuelian , Ren, Yangwu , Chao, Ann, Zhu, Junjie , Chen, Chih‐Yi , ScD, Chien-Jen Chen, Stevens, Victoria L. , Fraumeni, Joseph F., Lin, Kuang , Walters, Robin G., Chen, Zhengming, Chatterjee, Nilanjan , Gorlova, Olga Y. , Hsiung, Chao A. , Chanock, Stephen J, Rothman, Nathaniel , Kohno, Takashi , Lan, Qing, Kartsonaki, Christiana , Liu, Geoffrey , Field, John K , Matsuo, Keitaro , Wang, Junwen , Bojesen, Stig E , Grankvist, Kjell , Chen, Chih-Yi , Dai, Juncheng , Hung, Rayjean J. , Chen, Kexin , Shu, Xiao-Ou , Choudhury, Parichoy Pal , Lin, Dongxin , Zheng, Wei , Wang, Jiucun , Hu, Wei , Cai, Qiuyin , Hong, Yun‐Chul , Kim, Hee Nam , Wu, Yi-Long Lung Cancer , Richardson, Brian Douglas , Zhang, Tongwu , Wang, Zhaoming , Kim, Jin Hee , Albanes, Demetrius , Shin, Min‐Ho , Chung, Lap-Ping, Yang, Yang , Zheng, Hong , Dai, Hong , Yatabe, Yasushi , Kim, Young‐Chul , Daigo, Yataro , Kamatani, Yoichiro , Kobayashi, Masashi , Hosgood, Howard Dean , WATANABE, Shun-ichi J. , Miyagi, Yohei , Matsumoto, Shingo , Horinouchi, Hidehito , Tsuboi, Masahiro , Takahashi, Atsushi , Goto, Akiteru , Hara, Megumi , Nishida, Yuichiro , Takeuchi, Kenji , Matsuda, Koichi , Murakami, Yoshinori, Suzuki, Hiroyuki , Saito, Motonobu , Machiela, Mitchell J. , Oh, In‐Jae , Lee, Victor , Su, Wu‐Chou , Seow, Adeline , Kweon, Sun-Seog , Liu, Jianjun , Houlston, Richard S. , Tardón, Adonina , Chen, Chu, Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Kiemeney, Lambertus A. , Cox, Angela , Yuan, Jian-Min , Lazarus, Philip J. , Schabath, Matthew B. , Jiang, Shih Sheng , Chen, Chung–Hsing , Hsiao, Chin‐Fu , Yeager, Meredith , Liu, Jia , Berndt, Sonja I. , Li, Yuqing , Kang, Chang Hyun , Wang, Wen‐Chang , Xu, Jun, Guan, Peng , Yu, Chong‐Jen , Yang, Gong , Park, In Kyu , Cheng, Iona C. , Song, Bao, Wyatt, Kathleen , Ma, Hongxia , Zhu, Meng , Wang, Yifan , Qi, Tianchen, Iwasaki, Motoki , Wu, Guoping , Yang, Pan‐Chyr , Walters, Robin G. , Chatterjee, Nilanjan , Amos, Christopher I. , Shen, Hongbing , Rothman, Nathaniel , Lan, Qing , Zhang, Haoyu

JNCI: Journal of the National Cancer Institute | September 18, 2025 | Volume: 118 | Issue: 2 | Pages: 231-249

10.1093/jnci/djaf272 | PMID 41032288 Get It

Abstract Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
Reply to Hassan
Ramon‐Gonen, Roni , Granovsky, Yelena , Shelly, Shahar , Shahar, Shelly

Pain | September 17, 2025 | Volume: 166 | Issue: 10 | Pages: 2441-2442

10.1097/j.pain.0000000000003724 | PMID 40960619 Get It

Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis
Ng, Alexander , Asif, Aqua , Gómez‐Gómez, Enrique , Budäus, Lars, Barrett, Tristan , Radtke, Jan Philipp , Kesch, Claudia, Pham, Tho, Tewari, Ash , Cabello, M.A. Rodríguez , Mynderse, Lance A. , Borghi, Marcelo, Boesen, Lars , Singh, Paras B. , Renard‐Penna, Raphaële , Leow, Jeffrey J. , Pecoraro, Martina , Giannarini, Gianluca , Perlis, Nathan , López-Ruiz, Daniel, Rossiter, Marimo , Khetrapal, Pramit , Chan, Vinson Wai‐Shun , Haider, Aiman , Clarke, Caroline S. , Dickinson, Louise , Mitra, Anita, Margolis, Daniel J. A., Takwoingi, Yemisi , Emberton, Mark , Allen, Clare, Moore, Caroline M. , Kasivisvanathan, Veeru , Collaborators, PRIME Study Group, Briganti, Alberto , Evangelista, Alex, Freeman, Alex , Kirkham, Alex, Zlotta, Alexandre R. , Grey, Alistair, Ryan, Andrew, Borrelli, Antonella , Andrews, Antonette, Finelli, Antonio , Sancho, Arturo Platas, Baring, Ashley, Roy, Ashoke, Issa, Balqiisa, Israël, Bas , González, Carolina Aulló, English, Caroline, Zuiani, Chiara , Amate, Cristina, Yong, Daniel , Rozze, Davide, Lomas, Derek J. , Cannoletta, Donato , Chang, Eileen Wang, Chun, Felix, Zussino, Gaia , Antoch, Gerald , Gandaglia, Giorgio, Sauter, Guido , Thevarajah, Harini, Sorrell, Harriet, McBain, Hazel, Reis, Henning , Pita, Hernando Ríos , Potyka, Ingrid , Collavino, Jeanlou, Koshy, Jincy, Weng, Jing Yi , Withington, John, Egmond, Joke van, Piper, Jon, O’Brien, Jonathan , Rosa, José Valero, Sanz, Juan Luis , Quesada, Juan Mesa, Jannusch, Kai , Corr, Kateri , Haines, Kenneth, Umutlu, Lale , Quarta, Leonardo, Casarotto, Letizia, Gimeno, Linda , Moretti, Lucas, Laschena, Ludovica , Drewes, Lukas, Ostos, Manuel Sanchez, Peris, M., Volpacchio, Mariano , Prentice, Mark, Graefen, Markus , Soligo, Matteo, Boschheidgen, Matthias , Singhera, M., Wenzel, Mike, Fatterpekar, Monali, Al‐Nader, Mulham , Kachanov, Mykyta , Shaida, Nadeem , Muirhead, Nicola , Vasdev, Nikhil , Sanmugalingam, Nimalan , Nørgaard, Nis , Vicente, Pete, Incze, Peter , Ryan, Philip, Rouvier, Philippe , Mead, Phoebe, Mozer, Pierre, Viana, Públio César Cavalcante , Jiménez, Rafael E. , Novotta, Réka, Huang, Richard, O’Sullivan, Richard, Jepsen, Rikke Karlin , Frese, Robert, Clow, Rosemary, Al‐Monajjed, Rouvier , Lewis, Sara , Cashman, Sophia, Pizzolitto, Stefano, Lelie, S., Lindner, Sydney, Al‐Hammouri, Tarek , Sánchez, Teresa González, Reid, Thomas, McClure, Timothy, Maurer, Tobias , Peruzzi, Valeria, Tan, Wei Phin, Nahas, William Carlos, Chong, Yew Lam, Agarwal, Ridhi , Panebianco, Valeria , Girometti, Rossano , Ghai, Sangeet , COBELLI, Francesco DE , Pham, Tho, Taneja, Samir S. , Hu, Jim C. , Dias, Adriano Basso , Falkenbach, Fabian , Kastner, Christof , Schimmöller, Lars , Nathan, Arjun , Punwani, Shonit , Brew‐Graves, Chris , Brembilla, Giorgio , Margolis, Daniel , Giganti, Francesco , Collaborators, PRIME Study Group, Crestani, Alessandro , Sciarra, Alessandro , Evangelista, Alex, Kirkham, Alex P. S. , Grey, Alistair, Blanca, Ana , Bjartell, Anders , Tong, Angela , Warren, Anne Y. , Ciardi, Antonio , Rannikko, Antti , Stabile, Armando , Villers, Arnauld A. , Issa, Balqiisa, Hadaschik, Boris Alexander , English, Caroline L, Lee, Chau Hung , Caris, Christien T.M. , Stempel, Conrad von , Rozze, Davide, Messina, Emanuele , Chun, Felix, Gandaglia, Giorgio, Robert, G. , Caglič, Iztok , Theysohn, Jens Matthias , Grummet, Jeremy , Koshy, Jincy, Wilkinson, John, Withington, John, Egmond, Joke van, Deeks, Jonathan J , O'Brien, Jonathan, Quesada, Juan Mesa, Quarta, Leonardo , Orecchia, Luca , Moretti, Lucas, Rooij, Maarten de , Bicchetti, Marco , Gatti, Marco , Peris, María de los Desamparados Esteban, Roethke, Matthias Claudius , Monte, Maurizio Del, Wenzel, Mike, Takahashi, Naoki , Fleshner, Neil , Albers, Peter , Mead, Phoebe, Visschere, Pieter De , Huang, Richard, Shah, Syed Ahmar , Sanchez, Teresa González, Bathala, Tharakeswara K , Kwast, Theodorus van der , Reid, Thomas, Løgager, Vibeke , Prabhu, Vinay , Wagaskar, Vinayak Gorakhnath , Tan, Wei Phin, Nahas, William Carlos, Witjes, Wim P.J. , Chong, Yew Lam

JAMA | September 10, 2025 | Volume: 334 | Issue: 13 | Pages: 1170

10.1001/jama.2025.13722 | PMID 40928788 Get It

Importance Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally. Objective To assess whether biparametric MRI is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer. Design, Setting, and Participants A prospective, multicenter, within-patient, noninferiority trial of biopsy-naive men from 22 centers (12 countries) with clinical suspicion of prostate cancer (elevated prostate-specific antigen [PSA] level and/or abnormal digital rectal examination findings) from April 2022 to September 2023, with the last follow-up conducted on December 3, 2024. Interventions Participants underwent multiparametric MRI, comprising T2-weighted, diffusion-weighted, and dynamic contrast–enhanced (DCE) sequences. Radiologists reported abbreviated biparametric MRI first (T2-weighted and diffusion-weighted), blinded to the DCE sequence. After unblinding, radiologists reported the full multiparametric MRI. Patients underwent a targeted biopsy with or without systematic biopsy if either biparametric MRI or multiparametric MRI was suggestive of clinically significant prostate cancer. Main outcomes and measures The primary outcome was the proportion of men with clinically significant prostate cancer. Secondary outcomes included the proportion of men with clinically insignificant cancer. The noninferiority margin was 5%. Results Of 555 men recruited, 490 were included for primary outcome analysis. Median age was 65 (IQR, 59-70) years and median PSA level was 5.6 (IQR, 4.4-8.0) ng/mL. The proportion of patients with abnormal digital rectal examination findings was 12.7%. Biparametric MRI was noninferior to multiparametric MRI, detecting clinically significant prostate cancer in 143 of 490 men (29.2%), compared with 145 of 490 men (29.6%) (difference, −0.4 [95% CI, −1.2 to 0.4] percentage points; P = .50). Biparametric MRI detected clinically insignificant cancer in 45 of 490 men (9.2%), compared with 47 of 490 men (9.6%) with the use of multiparametric MRI (difference, −0.4 [95% CI, −1.2 to 0.4] percentage points). Central quality control demonstrated that 99% of scans were of adequate diagnostic quality. Conclusion and relevance In men with suspected prostate cancer, provided image quality is adequate, an abbreviated biparametric MRI scan, with or without targeted biopsy, could become the new standard of care for prostate cancer diagnosis. With approximately 4 million prostate MRIs performed globally annually, adopting biparametric MRI could substantially increase scanner throughput and reduce costs worldwide. Trial registration ClinicalTrials.gov Identifier: NCT04571840
Association between physician specialty and first-attempt intubation success in the emergency department
Besen, Bruno Adler Maccagnan Pinheiro , Carvalho, Julia M. Dorn de, Pedrollo, Daniel, Nogueira, Caio Goncalves, Figueiredo, Natalia Mansur P., Martins, Danilo, Baumgratz, Thiago Dias , Bergesch, Bruno, Costa, Diogo , Colleoni, Osmar , Zanettini, Juliana, Freitas, Ana Paula, Moreira, Nicole Pinheiro, Gaspar, Patrícia Lopes, Tambelli, Renato, Costa, Maria Cristina , Silveira, Samara, Correia, Wilsterman, Maria, Rafael Garcia de, Filho, Ubirajara A. Vinholes, Weber, Andre P., Castro, Vinicius da Silva, Dornelles, Carlos Fernando Drumond, Tabach, Barbara S., Stanzani, Gabriela , Gava, Thiago F., Silva, Gabriella Rennisy de Sousa , Oliveira, Giovanna Cardoso de, Bellolio, Fernanda , Alencar, Júlio César Garcia de , Maia, Ian Ward Abdalla , Investigators, on behalf of BARCO, Oliveira J E Silva, Lucas , Mullan, Aidan, Sandefur, Benjamin J. , Ward A Maia, Ian, Bellolio, M Fernanda , Besen, Bruno Amp , Silva, Lucas Oliveira J. e , Hellmann, Rafael von , Carvalho, Julia M. Dorn de, Hajjar, Ludhmila Abrahão , Miranda, Carlos Henrique , Tambelli, Renato, Guimarães, Hélio Penna , Mullan, Aidan F. , Oliveira, Giovanna Cardoso de, Investigators, on behalf of BARCO

European Journal of Emergency Medicine | September 10, 2025 | Volume: 32 | Issue: 6 | Pages: 430-436

10.1097/mej.0000000000001276 | PMID 40928066 Get It

Background and importance Emergency airway management in the emergency department (ED) is a high-risk procedure associated with patient outcomes. First-attempt success is a widely recognized quality metric, as multiple attempts are associated with an increased risk of peri-intubation complications. In Brazil, where emergency medicine is a recently established specialty, many ED are staffed by physicians without formal emergency medicine training. The association between emergency medicine training and intubation outcomes in this setting has not been well characterized. Objective To assess the association of physician specialty with first-attempt success and immediate peri-intubation complications in Brazilian EDs. Design Secondary analysis of a multicenter, prospective cohort study from the Brazilian Airway Registry Cooperation. Setting and participants This study included adult patients who underwent tracheal intubation in EDs between March 2022 and April 2024. Patients were excluded if the intubation occurred outside the ED, during cardiopulmonary resuscitation, or for elective procedures. Intubations performed by medical students were also excluded. Physicians were categorized by specialty as emergency medicine or nonemergency medicine. Outcome measures and analysis The primary outcome was first-attempt success; secondary outcomes included peri-intubation complications (severe hypoxemia, hemodynamic instability, and cardiac arrest). Multivariable logistic regression was used to assess the association between physician specialty and outcomes. Main results Among 2582 patients, 1087 (42.1%) were intubated by emergency physicians and 1495 (57.9%) by other physicians (mainly internal medicine and surgery). Intubations by emergency physicians were associated with a higher rate of first-attempt success [80.4 vs. 70.9%, adjusted odds ratio [aOR]: 1.63, 95% confidence interval (CI): 1.34–1.97]. There was also a higher odds of intubations without major complications (aOR: 1.20, 95% CI: 1.01–1.42). Conclusion In this study, there was a higher rate of first-attempt success in intubations performed by board-certified emergency physicians compared with other physicians working in Brazilian EDs.
AI Based Clinical Decision-Making Tool for Neurologists in the Emergency Department
Gorenshtein, Alon , Fistel, Shiri, Sorka, Moran , Telman, Gregory , Winer, Raz, Peretz, Shlomi , Shelly, Shahar , Shahar, Shelly , Gorenshtein, Alon , Peretz, Shlomi , Aran, Dvir

Journal of Clinical Medicine | September 10, 2025 | Volume: 14 | Issue: 17 | Pages: 6333

10.3390/jcm14176333 | PMID 40944092 Get It

Introduction: We aimed to prove integration of advanced machine learning methods within a robust ensemble framework can enhance clinical decision-support for neurologists managing patients in the emergency department (ED). Methods: We engineered an ensemble framework leveraging the capabilities of the Gemini 1.5-pro-002 large language model (LLM). The model was enhanced using prompt engineering and retrieval-augmented generation (RAG). Predictive modeling achieved by combining eXtreme Gradient Boosting (XGBoost) and logistic regression for optimal accuracy in clinical decision-making. Key clinical outcomes, such as admission and mortality, were assessed. A random subset of 100 cases was reviewed by three senior neurologists to evaluate the alignment of the AI’s predictions with expert clinical judgment. Results: We retrospectively analyzed 1368 consecutive ED patients who underwent neurological consultations, assessing their clinical features, diagnostic tests, and admission outcomes. Patients admitted were typically older and had higher mortality rates, shorter intervals to neurological evaluation, and a higher incidence of acute stroke compared to those discharged. For the primary analysis (n = 250), the Neuro artificial intelligence (AI) model demonstrated significant performance metrics, achieving an area under the curve (AUC) of 0.88 for general admission predictions in comparison to actual outcomes, an AUC of 0.86 for neurological department admissions, 0.93 for long-term mortality risk, and 1 for 48 h mortality risk. Our Neuro AI model predictions showed a strong correlation with expert consensus (Pearson correlation 0.79, p < 0.001), indicating its ability to provide consistent support amid divergent clinical opinions. Conclusions: Our Neuro AI model accurately predicted hospital admissions (AUC = 0.88) and neurological department admissions (AUC = 0.86), demonstrating strong alignment with expert clinical judgment.
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study
Tu, Wanzhu , Welch, Nicole , Tang, Qing , Kettler, Carla, Shah, Vijay H. , Nagy, Laura E. , Chalasani, Naga , Kerr, Thomas A. , Investigators, for AlcHepNet, Cotter, Thomas G. , McClain, Craig J , Cotter, T G , Dasarathy, Srinivasan , Gawrieh, Samer , Yu, Yunpeng , Sanyal, Arun J. , Szabo, Gyongyi , Bataller, Ramon A , McClain, Craig J. , Mitchell, Mack , Investigators, for AlcHepNet

Hepatology | September 9, 2025 | Volume: 83 | Issue: 6 | Pages: 1469-1482

10.1097/hep.0000000000001513 | PMID 40924794 Get It

Background & Aims: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes do not capture the added risk of return to drinking. We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH. Approach & Results: A cohort of 1127 participants: 712 AH patients, 256 heavy drinking controls without clinically evident liver disease, and 159 healthy controls, were prospectively followed for 6 months at 8 United States centers as part of the Alcoholic Hepatitis Network (AlcHepNet) consortium. Outcomes included mortality and a composite endpoint (AlcHepNet composite index) that included death, liver transplantation, hepatic decompensation (new onset/worsening ascites, HE, variceal bleeding), liver-related hospital admission, MELD increase ≥5, and return to drinking. Of 712 AH patients (age 45±10.7 y; 59.1% male), 558 (79.0%) had severe and 148 (21.0%) had moderate AH, 232 (32.5%) died, and 86 (12.1%) underwent liver transplantation. Mortality rates in moderate AH and severe AH were 0.7% versus 17.2% (30 d), 3.4% versus 26.5% (90 d), and 8.8% versus 30.5% (180 d), respectively (all p <0.001). Composite liver/alcohol use events were noted in 459 (64.5%) AH patients. Higher MELD score, lower mean arterial pressure, and baseline leukocytosis were associated with higher 90-day mortality in AH (all p <0.05). College education and higher ALP were associated with lower mortality. Heavy drinking controls had low mortality (n=3; 1.2%). Conclusions: This large observational study showed a high incidence of composite liver and alcohol-use events within 6 months, reiterating the need for early interventions.